
|Videos|November 17, 2021
Pharmacist Medication Insights: Hizentra for Primary Immunodeficiency
Author(s)Saro Arakelians, PharmD
Hizentra is indicated for the treatment of primary immunodeficiency in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.
Advertisement
Hizentra is an immune globulin subcutaneous (Human) (IGSC), 20%. It is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Emerging Biomarkers Open New Frontiers in Lung Cancer Therapy
2
Transforming HER2+ Metastatic Breast Cancer Treatment With Targeted ADC Therapy
3
Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC
4
Targeted α-Particle Radioligand Therapy Shows Promising Activity, Low Toxicity in SSTR2-Positive Neuroendocrine Tumors
5